Q4 2024 CVRx Inc Earnings Call Transcript
Key Points
- CVRx Inc (CVRX) reported a strong revenue growth of 36% year-over-year for Q4 2024, driven by a 41% increase in the US heart failure segment.
- The company successfully expanded its sales territories in the US from 38 to 48 by the end of 2024, enhancing market reach.
- CVRx Inc (CVRX) achieved significant reimbursement milestones, equalizing hospital reimbursement for inpatient and outpatient settings, which supports patient access.
- The transition to Category One CPT codes for Barostim Therapy is expected to improve prior authorization processes and unlock new market opportunities.
- The company ended 2024 with 223 active implanting centers, up from 178 in 2023, indicating successful market penetration and adoption.
- Despite revenue growth, CVRx Inc (CVRX) reported a net loss of $10.7 million for Q4 2024, slightly higher than the $9.2 million loss in the same period last year.
- The gross margin decreased slightly from 85% in Q4 2023 to 83% in Q4 2024, indicating potential cost pressures.
- Research and development expenses increased by 25% year-over-year, driven by higher clinical study and consulting expenses.
- The company experienced a reduction in sales territories in Europe, from six to five, reflecting challenges in international market expansion.
- Interest expenses increased due to higher levels of borrowings, impacting overall financial performance.
Greetings and welcome to the CVRx fourth quarter, 2024 earnings call at this time. All participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad as a reminder, this conference is being recorded.
It is now my pleasure to introduce Michael Vallie from ICR Health Care.
Good afternoon. Thank you for joining us today for CVRx Inc's fourth-quarter and full-year 2024 earnings conference call.
Joining me on today's call are the company's President and Chief Executive Officer Kevin Hykes and Chief Financial Officer Jared Oasheim.
The remarks today will contain forward-looking statements including statements about financial guidance.
The statements are based on plans and expectations as of today which may change over time.
In addition, actual results could differ materially due to a number of risks and uncertainties including those identified
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
